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Executive Summary
Problem: Safety concerns have existed for more than 40 years about how hazardous drug (HD)
exposure contributes to long- and short-term adverse health outcomes for healthcare workers
(HCWs). Careless handling may cause toxic residues to infiltrate hospital environments and
patient care areas, and can even be traced to patients’ homes. New government regulations will
require healthcare organizations to minimize exposure risks to HCWs by fully implementing the
U.S. Pharmacopeia (USP) Convention Chapter 800: Hazardous Drugs: Handling in Healthcare
Settings (USP, 2016) on December 1, 2019. According to Polovich and Olsen (2017), “The
implementation of the USP <800> Standards will represent an important step forward for nurses
and other potentially exposed HCWs” (p. 1).
Context: The proposed Doctor of Nursing Practice (DNP) project will implement an HD safehandling personal protective equipment (PPE) toolkit at an ambulatory cancer infusion center to
improve nurses’ adherence with the USP <800> Standards and hospital policies addressing PPE
use when handling, administering, and disposing of HD.
Proposed Interventions: Interventions for this project will consist of (a) an HD safe-handling
PPE toolkit for infusion nurses, (b) a PPE observation tool, (c) an expert panel discussion, (d) a
nurses’ skills session, (e) safe-handling adherence between observation and self-assessment
survey, (f) hazardous drug administration safe handling peer-to-peer checklist, and (g) a
performance dashboard to display progress.
Proposed Outcome Measures: Outcome measures include (a) 90% or higher compliance rates
with PPE use and (b) sustained adherence to USP <800> Standards and hospital policies for safe
HD handling to 100% by February 2020.
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Section II: Introduction
Problem Description
Healthcare organizations are preparing for the implementation of the USP Chapter 800:
Hazardous Drugs-Handling in Health Care Settings (USP <800>), where regulatory standards
will provide enforceable safe-handling protections for all HCWs to minimize HD exposure risks
(USP, 2016). As USP <800> changes how HDs are managed, organizational efforts to educate
staff and ensure acceptance from HCWs will drive new worker safety protections (Andrews &
Dill, 2018). Despite scientific evidence of known exposures and adverse health outcomes related
to residue exposure, resistance to the use of PPE or other safe-handling measures during
preparation, administration, and waste disposal continue among infusion nurses. Adverse health
outcomes may include genetic changes, developing certain cancers, birth defects and fetal
abnormalities, organ toxicity, and infertility, among others. According to Hennessy and Dynan
(2014), “Resistance is based on the denial of risk, insufficient information, lack of policy
enforcement or regulation, or lack of provision of safe-handling devices” (p. 497).
Infusion nurses have not well received policy efforts to change from recommended PPE
guidelines for HD administration to mandatory requirements. Studies have shown that nurses’
PPE use is inconsistent across the country. The primary focus for implementing this evidencebased practice (EBP) initiative is two-fold: (a) USP <800> requires HCWs to wear proper PPE
when handling HDs, and (b) nurses need to consistently adhere to USP <800> standards and
organizational policies during patient care. The proposed quality improvement (QI) intervention
is of interest to the organizations’ “Environment of Care” Workstream Committee whose
purpose is to prepare ambulatory health care units for compliance with USP <800> Standards.
The outcomes are of interest to the organizations’ Cancer Committee because it satisfies the
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“Quality Improvements” Standard 4.8 of the Commission on Cancer Program accreditation
requirements. Until recently, the organization’s efforts have been placed on developing inpatient
compliance, with minimal attention paid in ambulatory care settings. To address infusion nurses’
reluctance to wearing PPE, the organization must understand how it contributes to this
phenomenon, eliminate barriers to allow for best practice, and implement changes to improve
safety and compliance.
The setting will be an ambulatory infusion center (AIC). The AIC has 36 infusion
treatment chairs available for chemotherapy and non-chemotherapy patients. The study will
involve the observation of experienced infusion nurses, defined as having two or more years of
experience in chemotherapy administration, to determine the baseline compliance rate of PPE
use with HD handling. All nurses are required to possess a chemotherapy and biotherapy
certification card that demonstrates sufficient training and competence in the area of HD
administration processes and drug knowledge. The first goal is to observe at least 90% of the
nurses prepare, administer, and dispose of HDs over a four-week period. Fifteen nurses are
eligible to participate in the quality improvement (QI) project. At the organization where the
project will be implemented, policies specific to PPE requirements with HD handling are
currently under review and revision. However, the Oncology Nursing Society (ONS) states that
standard-specific gloves (ASTM D6978), non-permeable gowns, face masks and eye shields (or
goggles), and respirator masks be readily available for PPE use at a minimum. The project will
follow the ONS guidelines for PPE use with HD handling until policies have been approved for
the infusion center.

Available Knowledge
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Hazardous drug residues pose a real threat to the health and wellbeing of staff, patients
and families, and the environment when left uncontrolled or mismanaged. The National Institute
for Occupational Safety and Health (NIOSH, 2016) reported more than eight million HCWs in
the United States are potentially exposed to HDs. Furthermore, HCWs with long-term, low-level
occupational exposure have shown an increased risk of adverse reproductive outcomes and other
unwanted health issues (Connor, Lawson, Polovich, & McDiarmid, 2014; Hon, Teschke, Shen,
Demers, & Venners, 2014). McDiarmid and Condon’s (2005) research identified a 20% increase
in chromosomal abnormalities of HCWs who had a ‘moderate’ level of hazardous drug handling
(>100 handling events of chemotherapy within six weeks). Lack of diligent organization and
worker accountabilities, inconsistent oversight, and environmental exposure have caused
irreversible harm and death in some cases (Smith, 2010). Toxic residues found on common
healthcare surfaces may spread to patient homes, exposing cohabitants, family pets, and the
environment (Bohlandt, Sverdel, & Schierl, 2017; Connor, Zock, & Snow, 2016; Yuki, Sekine,
Takase, Ishida, & Sessink, 2013).

PICOT Question
Would the development of an HD safe-handling PPE toolkit improve infusion nurses’
compliance and adherence with PPE use during HD handling and comply with USP <800>
standards and hospital policies for HD safe handling by February 1, 2020?
Literature Review
I conducted a literature review using CINAHL, Cochrane Library, and PubMed databases
to locate current information on the health hazards of residue exposure and recent EBP
recommendations to improve PPE use in nurses. More than 50 articles from 2005 to 2019 were
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located in the database search, with 15 selected for further review. Findings demonstrated a clear
and present danger regarding HD exposure and the need to implement mandatory EBP policies
for PPE use and environmental oversight. Excluded articles were those that focused on hospital
HD administration, routes of administration other than intravenous (IV), anesthesia HDs, and
occupations outside the healthcare setting. Keywords for the search included hazardous drugs,
occupational health, protective equipment, safety standards, and USP <800>. Final literature
selection criteria were determined after analyzing the strengths, weaknesses, limitations, and
quality of evidence using the Johns Hopkins Nursing Evidence-Based Practice Tool (Dearholt &
Dang, 2016). There were five Level IA, four Level IIA, and six Level IIIA quality ratings for the
selected articles, which represents a quality approach for selecting the evidence for this project.
A summary of the evidence is available in an evaluation table (see Appendix B). The articles and
research studies identified three themes: (a) HD residues found in patient homes after treatment,
(b) organizational responsibilities, and (c) nurses’ responsibilities to practice and provide safe
care for others, including the environment of care.
Hazardous drug residues found in patient homes. Yuki et al. (2013) tested the urine of
family members of three cancer patients who received at least one of two antineoplastic drugs
(cyclophosphamide [CP] and fluorouracil [5-FU]) during the first 48 hours after IV
chemotherapy treatment. The objectives were to determine if (a) any detectable levels of HD
agents exposed family members, (b) whether environmental contamination occurred inside the
home, and (c) how long a drug remained in the patient’s urine 48 hours after treatment. Urine
samples were collected from patients and patient family members, and swipe tests were obtained
from common home surface areas to detect if CP or 5-FU residues were present. Predetermined
acceptable drug levels for CP were 0.01 and 5ng/ml urine for 5-FU. Cyclophosphamide was
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detected in eight of 12 swipe tests (0.03 – 7.34 ng/cm2) in one of the homes. Swipe tests in
homes of treated patients with 5-FU reported drug levels below the predetermined threshold;
however, there are currently no defined acceptable levels of HD exposure.
Swipe tests from toilet seats and bathroom sink faucets had the highest level of HD
residue (3.02 and 0.57 ng/cm2); floors around toilets and bathroom doorknobs measured 0.03
and 0.09 ng/cm2. Most importantly, patients continued to excrete antineoplastic drugs at low
levels over more than four days through urine, feces, and standard breathing patterns. Family
members who handle potentially contaminated waste products, such as urine, stool, vomit, or
other excreta, should receive specific safe-handling instructions to control the spread of
contaminants in the home setting. While most research focused on controlled health
environments, it is imperative that patients receiving HDs be better informed and prepared in
case of potential exposure situations to families and friends.
Bohlandt et al. (2017) conducted an environmental and biological study inside 13 homes
of treated cancer patients to confirm potential HD residues on household surfaces. The
researchers wanted to determine whether HD levels were measurable in the cohabitants of
treated patients. Thirteen study participants received outpatient IV chemotherapy in an oncology
infusion clinic. The researchers obtained 265 samples from home surfaces, including bathroom
toilets, floor and sink handles, and kitchen surfaces. Every specimen had substantial levels of HD
residues, but cohabitant urine samples did not detect any trace of IV chemotherapy residues.
Crickman and Finnell’s (2016) systematic literature review covered 13 years of articles,
from 1979 to 2014, to understand the need to implement HD control measures in different
settings. Healthcare workers, especially those who are not responsible for medication
administration but clean up after a treated patient, are among the highest at-risk population. The
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findings are worrisome because families often become primary caregivers after chemotherapy
treatment. Recommendations regarding PPE selection and choice, HCW competencies, increased
professional oversight, and medical monitoring of high-risk staff will be mandated requirements
in the USP <800> regulations. These articles indicated that HCWs must also practice safe
handling in controlled settings to minimize personal risk; they must also educate and inform the
public.
Organizational responsibilities. Clark, Zickar, and Jex (2014) developed a field study
investigating the influence of role definitions on the association between safety climate and
employees’ organizational citizenship behavior. Providing safe working conditions requires a
significant commitment on the part of leadership and stakeholders. Unfortunately, an
organizations’ obligation to provide safe, patient-centered care often overshadows or conflicts
with ensuring that staff also deserves safe working conditions to provide that care. For example,
scheduling patients for infusion therapy requires an acuity-based, decision-making process, yet
nurses are often scheduled to treat far more patients than is safe with HD administration. Clark et
al. stated that nurses who feel appreciated, protected, and respected by their organization are
more likely to go above and beyond expectations to provide optimal patient care.
In 2017, He, Mendelsohn-Victor, McCullagh, and Friese completed a cross-sectional,
multi-state survey offered to Oncology Nursing Society (ONS) members (N = 654) to examine
whether the organization’s safety culture correlates to nurses’ use of PPE. The study involved
nurses working in ambulatory care centers in three states across the United States; 67% of the
oncology nurses responded to the survey. One tool used to collect data was the Revised
Hazardous Drug Handling Questionnaire (Martin & Larson, 2003; Polovich & Olsen, 2017). The
sample mean for the PPE-use score was 2.4 (SD = 1.0) out of a maximum score of 5.0.
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Nurses self-reported that 26% were involved in an HD spill, 90% wore only one pair of
chemotherapy-approved gloves, and other PPE supplies were infrequent. He et al. (2017) found
that if nursing workloads increased by one patient, the odds of an HD spill increased by 3.0%
(OR = 1.03, 95% CI [1.01 – 1.06], p = 0.01). He et al. recommended that nurse managers
monitor and adjust patient acuity, ensure that PPE is readily available, and provide ongoing HD
training to prevent adverse events. Furthermore, the authors stressed the need for organizations
to commit to a culture of safety that may include modifying the nurses’ workload and
environment, if necessary, to accommodate safe-handling practices and self-protection during the
HD-handling process (He et al., 2017).
Nurses’ responsibilities to provide safe care. The most recent study by Friese, Yang,
Mendelsohn-Victor, and McCullagh (2019) concluded that despite decades of research, PPE use
remains suboptimal and that professional organizations, policymakers, clinical experts, and
healthcare systems align to guide best practices to ensure public safety. The randomized
controlled study, from 2015 to 2017, involved 12 academic healthcare ambulatory oncology
centers across the United States and included nurses who handled HDs (N = 396). All data were
collected from a secure website where participants accessed learning modules and completed
questionnaires to self-report PPE use. The intervention did not improve adherence among
participants. Therefore, the authors suggested that nurse leaders standardize education and HD
policies and procedures and enforce personal accountability regarding safe-handling steps and
PPE use (Friese et al., 2019). Under USP <800>, efforts to provide oversight and safe handling
across oncology settings will no longer be considered recommendations or guidelines.
DeJoy et al. (2017) examined predictors of PPE use, safe-handling components, and
adverse events associated with HD exposure in nurses (N = 1,814) and concluded that adherence
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to recommendations is inconsistent. Interestingly, PPE use was worse and less predictable among
more experienced nurses during chemotherapy administration than among their less experienced
colleagues. The study assessed organizational safety climate and nurses’ perceived safety climate
regarding PPE, engineering controls, and adverse events associated with IV HDs. DeJoy et al.
found that nurses’ perceptions about exposure risks were low and that they understood
organizational policies to merely be guidelines for PPE use. A comprehensive health and safety
program emphasizing hazard controls is critical to promote safer behavior among all HCWs.
Summary of the Evidence
The literature review suggests that HD controls are inconsistent and that workplace
contamination may lead to HCW and patient exposure to toxic agents. Both international and
national research conducted in ambulatory oncology practices support stricter, even mandatory,
PPE utilization and endorse environmental and biological monitoring for the detection of
harmful residues, similar to radiation exposure monitoring of HCWs (Bohlandt et al., 2017;
Boiano, Steege, & Sweeney, 2014). Summaries from the literature review reveal gaps in safety
controls. Researchers concluded with recommendations for HD controls that focus on (a) better
engineering controls, such as closed-system transfer devices (CSTDs) and biologic safety
cabinets; (b) administrative controls, such as updating policies and procedures and improving
access to information; (c) work practice controls, such as acuity-based scheduling and reducing
workloads and crowded spaces; and (d) ensuring the mandatory use of PPE. Furthermore, nurses
are aware of the hazards associated with exposure but continue to exhibit risky behavior.
Rationale/Conceptual Framework
The Orem model of nursing or self-care deficit nursing theory was developed by nursing
theorist Dorothea Orem and covers a broad spectrum of general concepts for nursing
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consideration and application (Alligood, 2014). The theory is comprised of three related parts:
(a) the theory of self-care, (b) the theory of self-care deficit, and (c) the theory of nursing
systems. Some of the theory’s relativity to this project include: a person’s knowledge of potential
health problems is needed for promoting self-care behaviors, the prevention of hazards to human
life and wellbeing, and responsibility for their care, as well as others who require care (Vincent,
Pischke-Winn, Pakieser-Reed, & La Fond, 2016). This model depicts how health professionals
have as much of a responsibility to care for themselves as they would care for others (Younas,
2017).
Donabedian’s conceptual model, developed in 1966, provides a framework for
developing, implementing, and evaluating this intervention (McDonald et al., 2007). Applying
the components of the model to this project include the assessment of structures, processes, and
outcomes relative to ambulatory oncology infusion centers associated with the management and
safe handling of chemotherapeutic agents. According to Donabedian, the physical setting would
be determined as the Cancer Center’s AIC. The elements would include the mission and values
of the organization, leadership skills, staff knowledge levels, adequate staffing and scheduling,
suitable workspace, and patient population. Other elements to support a safety culture include
having access to HD waste bins, chemotherapy spill kits, and CSTDs.
The process includes interventions that occur within the AIC that contribute to the
outcomes of safe drug delivery, such as HD administered by oncology trained nurses.
Developing standard work and tip sheets that outline the responsibilities and steps for each stage
in the HD-handling process, including any associated interdisciplinary tasks, are aspects of
process outcomes. Evidence-based guidelines and regulatory mandates specific to HCWs and
patient safety are specified in the USP <800> Standards.
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Finally, an outcome is the final product combining both structure and process. A
favorable outcome would have a sustainable structure and process that reduces the risk of HD
contamination at all stages of handling. Poor outcomes allow for failures, such as inconsistent
use of PPE by nurses or other processes contrary to EBP recommendations. Different relevant
outcomes include improved patient perception of safety scores from Press Ganey surveys and
reduced costs due to employee health matters related to HD exposure. Nurses’ attitudes and
perceptions about protecting themselves to protect others will align with policies and procedures
and other best practice initiatives and comply with the USP <800> Standards.
Specific Aims
The objectives are to develop, implement, and evaluate an HD safe-handling PPE toolkit
to learn if infusion nurses’ adherence to PPE use will improve to 100% with HD handling and
comply with the USP<800> standards and hospital policies for safe handling by February 2020.
The specific aims of the project are to determine if (a) based on direct observation, nurses
comply with USP <800> requirements and hospital policies for HD handling when administering
and disposing of IV chemotherapy (as defined in the PPE toolkit); (b) based on nurse selfassessment, PPE standards and hospital policies for safe handling were followed at least 90% of
the time; and (c) any differences are noted in nurses observed and self-assessed adherence to
PPE standards and hospital policies for safe handling. If differences are noted, additional peerto-peer coaching will be considered until 90% compliance has been reached.
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Section III: Methods
Context
Personal protective equipment use has been defined in the literature as a critical element
required for handling HDs at any step in the process. The administration process for ambulatory
infusion nurses to safely administer HDs will require enhanced training on selecting, donning
and doffing PPE, and proper disposal of contaminated equipment. According to Friese et al.
(2019), “Education and engagement of nursing personnel are not sufficient to improve PPE use.
However, systematic approaches may result in improved practice” (p. 255). The proposed
intervention will include the development of an HD safe-handling PPE toolkit to guide best
practice with antineoplastic drug administration and proper waste disposal methods.
The key stakeholders of the proposed DNP project include staff in the AIC where the
project will take place, the Assistant Unit Manager (AUM), the Cancer Center Executive
Director, the Director of Cancer Services, the Cancer Committee, and the “Environment of Care”
Workstream Committee. Also, the USP <800> Committee will be interested in the outcome of
the DNP project because the results may be applicable to other hospital-based AICs within the
healthcare system. The Cancer Committee has chosen this project as one of its’ Quality
Improvement (QI) initiatives for 2020. Each year the Cancer Committee must report QI results
directly to the Commission on Cancer (COC) Programs to maintain accreditation. This project
meets Program Standard 4.8 (Quality Improvements, see Appendix B). Finally, the USP <800>
Standards are not optional, and the Cancer Center must comply with all applicable standards.
Proposed Intervention
The purpose of implementing an HD safe-handling PPE toolkit is intended to gain better
PPE adherence from infusion nurses in the AIC and to create an environment where a culture of
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safety can exist. The DNP project will be conducted in an AIC adjacent to a large tertiary
medical center campus. The AIC consists of the following healthcare personnel: 15 registered
nurses, two patient care associates (previously called nurses’ aides), one Assistant Unit Manager
(AUM), one unit secretary, and five oncology nurse practitioners (NPs). Nurses generally work
10-hour shifts from 8:00 a.m. to 6:30 p.m. The AIC is open seven days per week. The AUM
reports directly to the Director of Cancer Services weekly, the Executive Director of Cancer
Center monthly, and to the Cancer Committee at least quarterly.
The Cancer Committee provides program oversight and also ensures compliance with all
rules and regulations set forth by federal, state, and local authorities. The Committee is also
responsible for engaging in QI projects centered on quality patient outcomes and patient safety to
meet the COC standards for Cancer Centers (see Appendix B). This committee is aware of QI
methodology and familiar with the elements of Donabedian’s conceptual framework of structure,
process, and outcome. However, the COC has outlined specific steps for project compliance,
which includes creating an independent QI committee to oversee all cancer center projects. A
description of the COC’s project steps is described in a Basic Steps of Standard Compliance
Flow Sheet (see Appendix C). I will work directly with the QI Committee on this project.
The interventions will be implemented over five months, from September 2019 through
February 1, 2020. Once the project is completed, and evidence of improvement in nurse
adherence with PPE use and compliance with hospital policies and USP <800> standards are
achieved, the plan is to analyze and report the interventions’ results to other executive leadership
in the health system. To ensure Internal Review Board (IRB) approval is not required for the
implementation of the project, I will submit a DNP Statement of Non-Research Determination
form to my DNP Committee (see Appendix D), as well as provide a request for review to the
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healthcare system’s IRB to confirm this is a QI project. The interventions will consist of: (a) the
development of an HD safe-handling PPE toolkit, (b) PPE observation tool, (c) observations of
chemotherapy safe-handling adherence, (d) expert panel discussion, (e) nursing skills session, (f)
safe-handling adherence between observation and self-assessment survey, (g) hazardous drug
administration safe handling peer-to-peer checklist, and (h) the use of a performance dashboard.
Each of these interventions will be described in detail.
Hazardous drug safe-handling PPE toolkit. The toolkit will contain available evidence
as described in the literature, align with the policy manual, and become a practical guide for
frontline infusion clinicians. The toolkit will be divided into three sections: Part A (Portfolio of
the Evidence), Part B (How to Implement Interventions), and Part C (Resource Tools). Part A
will contain current EBP research and methods (evidence table) and hospital and AIC policies
for safe HD administration. Part B will include a PowerPoint training module for HD PPE
selection. Part C will contain useful tools, such as the confidential Pre-Observation tool,
hazardous drug administration safe handling checklist for peer-to-peer feedback, and
observations of chemotherapy safe-handling adherence tool. Furthermore, a list of common HDs
provided by the ambulatory care pharmacy will be added for reference and include exposure risk
levels and specific PPE requirements for potential low-, moderate-, and high-risk situations.
Confidential pre-observation assessment. Confidential observations of staff nurses’
handling, administering, and discarding chemotherapy waste will be done by the DNP student, a
clinical nurse educator, two oncology registered NPs, and one infusion pharmacist to determine
the baseline level of adherence using an established PPE observation tool (Hennessey & Dynan,
2014). I will collect and analyze results to determine the current adherence rate of PPE use
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before the intervention based upon recommendations from the Cancer Committee and
“Environment of Care” Workstream Committee groups.
Expert panel discussion. An educational session introducing the USP <800> Standards
related to PPE use will be provided by a panel of oncology certified nurses, an occupational
health nurse, a clinical nurse leader, medical oncologist, and pharmacist to increase awareness of
personal risks associated with HD exposure and to address potential and actual barriers that
hinder compliance in the current practice environment.
Nurse skills session. The AIC nurses will attend a 2-hour skills session to introduce them
to the concepts of the USP <800> Standards within the department. Orem’s self-care deficit
theory will be used to teach how the theory applies to personal safety and nursing practice. The
nurses will also receive feedback on the current state of safe-handling methods in the unit and
how the focus of the DNP project includes improving the workplace environment to promote a
culture of safety. A PPE demonstration and practice session will be provided, and a peer-to-peer
tip sheet and the toolkit will be introduced.
Safe-handling adherence between observation and self-assessment. A Qualtrics
survey will be sent via email to infusion nurses to obtain self-assessments of adherence to PPE
and compliance with organizational policies. Results will be compared to actual observations in
the AIC by trained staff.
Hazardous Drug Administration Safe Handling Checklist (Peer-to-Peer Tool). The
organization has obtained permission from the authors to utilize this tool created by two nurse
researchers, Martha Polovich and Mikaela Olsen. The tool will be useful in providing
instructions and feedback on several different HD administration techniques such as IV
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infusions, IV push medications, intramuscular and subcutaneous injections, and oral drugs,
including liquid preparations (Polovich & Olsen, 2017, p.96-97).
Performance dashboard. A visual display to create transparency and ownership will be
posted on the huddle board identifying critical elements of the intervention phases. Metrics will
be discussed in daily huddles to encourage participation, brief staff on the current status of the
project, and to develop the concept of an environmental safety culture (OSC).
Gap analysis. Better education is needed to ensure that employers and HCWs are fully
aware of the risks and potential adverse health consequences of exposure to these toxic drugs
(Boiano et al., 2014). For example, nurses who work in high exposure environments understand
the inherent risks, yet compliance may be ignored, as evidenced by the lack of PPE use.
Additional gaps specific to the AIC include scheduling demands and workload pressures placed
on pharmacists and nurses. Research shows that the average patients per day significantly
influence total HD precautions. It is safe to say that HD precautions occur with fewer patients
per nurse, yet patient acuity levels may change dramatically throughout the day, jeopardizing
real-time safety. The gap analysis outlines common issues concerning PPE use and the
organizations’ conflicting agenda (see Appendix E).
Infusion managers may benefit from a unit-specific acuity scheduling template and a
toolkit outlining the risk levels of exposure to staff, including facilitating clinician input on the
decision to lower workloads and eliminate structural barriers to safe handling (MendelsohnVictor, McCullagh, & Friese, 2017). Hospital, pharmacy, and unit-specific interventions could
contribute to a more reliable work environment balance. Safe-handling practices, such as PPE
worn by nurses, reduce exposure risks, and the likelihood of adverse health effects from
antineoplastic drug residues (NIOSH, 2016). However, not all exposure risks involve nursing
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practice, as each step in the handling process, should be managed appropriately. Evidence-based
practice, policies and procedures, engineering controls, unit-based workplace designs, and the
HCWs commitment to improving safety must guide processes and outcomes (Callahan et al.,
2016).
Gantt chart. The project will be divided into four implementation phases, as outlined in
the Gantt chart (see Appendix F). The first phase will commence in September 2019.
Confidential observations of the AIC infusion nurses’ handling, administering, and discarding
chemotherapy will be completed by the DNP student, a clinical nurse educator, two oncology
NPs, and one infusion pharmacist to determine the baseline level of adherence with safe handling
using the established PPE observation tool by Hennessey and Dynan (2014). The second phase
will take place in October 2019, where an expert panel discussion will be held for all staff in the
AIC. The panel will consist of oncology certified nurses, one occupational health nurse, a
clinical nurse leader, infusion pharmacist, and medical oncologist. Nurses will also be provided
access to an online survey to perform a self-assessment of safe-handling adherence. Beginning
phase three in November 2019, individual nurse audits will be performed to assess compliance
with PPE use, and immediate peer-to-peer feedback will be provided to encourage best practice.
Phase four will commence on December 1, 2019. Nurses’ adherence will be expected to comply
with the USP <800> regulations and current hospital policies and procedures for PPE use with
all HD handling.
Work breakdown structure. The purpose of the work breakdown structure (WBS) is to
have a plan and infrastructure, supporting documentation and metrics tools, comprehensive
education strategies, and a monitoring plan to maintain fiscal responsibility and increase chances
of sustainability (see Appendices G, H, and I). Since the hospital has been proactively preparing
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for hospital and pharmacy compliance, this project will serve as an adjunct to other
administration processes requiring PPE use and ensure that the cancer center is provided with the
resources necessary for USP <800> readiness.
There are five phases of development in the WBS: (1) initiation, (2) planning, (3)
execution, (4) control, and (5) closeout. During the initiation phase, the project manager will
attend the organization’s USP <800> committee meeting to share information about the
proposed project plan and gather recommendations from the group. The USP <800>
environment of care committee will sign and approve a charter. The PPE workgroup will
develop a preliminary scope statement and solidify team member participation during the
planning phase. The DNP student will develop the final project plan, with the cancer committee
accepting for final approval.
The execution phase includes a kickoff meeting, verifying and validating the USP <800>
PPE requirements, introducing the toolkit, deciding on the quantity of PPE per unit, testing in the
AIC, and completing the PPE toolkit. Staff training and Go Live date will be determined. The
control phase of the WBS includes project management, project status meetings, risk
management, and updating the project management plan. Finally, the closeout phase is one of the
essential aspects of the project. An audit procurement and lessons learned session is instrumental
because all of the completed steps will be analyzed and reported to various committees involved.
All files and records will be collected and archived. Formal acceptance of the toolkit as an
important resource for AIC nurses will be realized.
Responsibility/Communication plan. The proposed QI intervention is part of an
organizational work stream committee that exists to address the environment of care readiness
plan related to USP <800>. The initiative is also of interest to the cancer committee because it
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satisfies a mandatory requirement issued by the COC practice (see Appendix J). The cancer
committee will make an overall recommendation to the work stream committee to develop,
implement, and report on the USP <800> Standards for the entire cancer center. However, a
smaller workgroup committee will focus on the AIC project where HCW exposure risks are the
highest. Project charter team members will meet weekly to discuss the next steps and progress
toward agreed upon goals.
A separate PPE workgroup will oversee the selection of protective equipment and
measures while assessing the financial impact on the AIC and organization. Many healthcare
personnel will assist with gathering content to be used in the toolkit. Training and monitoring of
nurses will be a combined effort by the AUM, clinical nurse educator, and others. The DNP
student will work cohesively with each of the groups throughout the process to ensure timely
coordination and communication, thereby providing efficient use of available resources and time.
SWOT analysis of the current state. The SWOT analysis (strengths, weaknesses,
opportunities, and threats) is a useful tool for identifying many factors that may impact the
success of the project (see Appendix K). The following summary of the findings is discussed
below.
Strengths. A system-wide approach in how the organization will address the new
standards is now in process. Executive leadership and frontline managers are working to identify
gaps with HD handling that include transporting, receiving, storing, preparing, administering,
and disposing of HD waste. Supplies necessary for safe handling are under review. Standards of
practice are being aligned across the healthcare system to improve communication and
understanding among physicians, pharmacists, nurses, and many others involved in these critical
steps.
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Weaknesses. The most significant flaw is the nurses’ resistance to wearing PPE with HD
administration in the AIC. Even after focused training sessions and reminders in the past, nurses
remain complacent (Friese et al., 2019). Without addressing negative attitudes and beliefs toward
PPE use, improving personal safety will remain unsustainable. Nurses must understand that
personal safety will be jeopardized, and diligent PPE adherence will prevent potential short- and
long-term adverse health effects. Policies and procedures for HD handling are contradictory in
some settings and merely indicate PPE use as a guideline. However, a renewed focus on USP
<800> creates the urgency to reevaluate processes and include the mandatory requirements based
on exposure risk factors. Also, increased costs associated with purchasing PPE, waste
management, and decontamination wipes are unpredictable.
Opportunities. Opportunities to comply with USP <800> specific to PPE use are making
national news and bringing awareness to the public about the risks of HD residue exposure in
their communities. Local leaders and waste management services are reviewing external pressure
from communities to control environmental HD waste. Increasing demand for patient education
provides opportunities for nurses to engage the public on safe-handling awareness, not only in
controlled healthcare settings but also inside their own homes.
Threats. Threats to meet upcoming USP <800> Standards for PPE use may be associated
with the high cost of equipment, regular and random monitoring of the HCW and AIC
environment, inability to maintain and recruit qualified nurses experienced with HD practices,
and a lack of focus on ambulatory care practices during program development. Also, there may
be a loss of funding in the coming years for healthcare programs that strive to meet the demands
of the 21st Century Cures Act. This legislation will increase Medicare infusion access to eligible
patients and impose significant financial disincentives to pharmacy services. It is vital that PPE
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and waste management strategies remain part of this new legislation to prevent the dumping of
chemical waste into communities and to ensure accessibility to appropriate PPE.
Proposed Budget
The AIC is the highest user of PPE in the patient care setting within the organization for
HD handling. With 2,800 patient visits projected per month in 2020, the costs of providing PPE
to HCWs is daunting. The annual cost alone accounts for an increase in the budget of over 20%
in 2020. Purchasing departments generally choose contracted vendors to get better pricing;
however, various committees are reviewing several other non-contracted vendors to improve
pricing options. Nursing is evaluating different PPE products for comfort and ease of use with
hopes to improve adherence and compliance.
Nonmonetary benefits include ethical, moral, and harm reduction efforts to protect staff
and patients that cannot be quantified into a dollar amount. Interestingly, efforts are underway to
create a national registry where health care workers can report HD exposures that include
chemotherapy and report adverse side effects experienced such as headache, dizziness, nausea,
hair loss, miscarriage, and fertility problems (Friese, et al., 2019). A toolkit will become a quick
and useful staff resource to guide best practice. The budget estimates document (see Appendix
L) is a rough draft depicting financial considerations for implementing the project. Future
dissemination of the toolkit is excluded. Projections include staff education, a learning module,
expert panel discussion, pre- and post-observations of PPE use, and peer-to-peer feedback tip
sheet tool.
Proposed Outcome Measures
The PPE observation tool will be used to collect pre-intervention data to evaluate the
current state of adherence to PPE use with HD administration. To assess observations of

USP <800> AND THE PPE PROJECT

25

handling, administering, and disposing of chemotherapy, a 15-item yes or no nurse skill checklist
will be used. To retrieve self-assessments of nurses’ adherence to PPE use and to follow
organizational HD policies, a 9-item questionnaire using a 5-point Likert scale response set,
ranging from 0 (never) to 4 (always) plus a not applicable option, will be given. The content for
this tool is derived from NIOSH, ONS guidelines, USP <800> Standards, and the healthcare
organization’s updated policies for HD safe handling. Also collected and analyzed will be nurse
demographics and professional characteristics through self-assessment survey questions using
checkbox and fill-in-the-blank responses.
Proposed Analysis
Data analysis will involve describing the nurse skills checklist frequencies and selfassessment of RN characteristics using medians and quartiles of counts and percentages for all
categorical variables. Mean scores for the 9-item self-assessment questionnaire on PPE
recommendations will be calculated by averaging responses across administration,
disconnection, and disposal of chemotherapy. After matching factors for the nurse skill checklist
and self-assessment questionnaire, data will be compared to learn if differences exist in
adherence to PPE recommendations and hospital policies for safe chemotherapy handling. All
analyses will be two-tailed and will be analyzed at a significance level of 0.05, SAS Version 24.
Ethical Considerations
One of the core Jesuit values is forming and educating agents of change, which means
teaching behaviors that reflect critical thought and responsible action on moral and ethical issues.
Infusion nurses must change attitudes and behaviors on using PPE because of the high-risk
nature of harm due to HD contamination. It is morally and ethically irresponsible to subject
patients and families to harmful HD residues because of personal convictions. The American
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Nurses Association (ANA, 2015) ethical standard that relates to this evidence-based project is
Provision 3, “The nurse promotes, advocates for, and protects the rights, health, and safety of the
patient” (p. 9).
Provision 3.4 states that nurses have a professional responsibility to promote a culture of
safety. This provision extends beyond reporting events and errors that occur to patients and
includes “adherence to policies that promote patient health and safety” (ANA, 2015, p. 12). This
QI project hopes to empower nurses to behave more responsibly to protect patients from HD
exposure while in their care. Also, nurses will educate other staff and the public by rolemodeling proper PPE use with HD handling. Efforts will be made to minimize the psychological
stress patients, and caregivers may feel while observing the PPE intervention by informing them
of the new regulations to improve patient and nurse safety with HD administration. Nurses are
encouraged to incorporate HD education into their teaching plan via verbal and written
communication methods and emphasize how to prevent home environmental contamination.
Since the focus of this project was on QI, it does not require an IRB approval for
implementation, per the University of San Francisco’s IRB. The project was evaluated and
approved as a QI project through the University of San Francisco School of Nursing and Health
Professionals. However, the healthcare organization requires IRB evaluation, so the DNP project
will be referred to the committee for comments and approval.
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Section IV: Discussion
Limitations
The hospital has organized multiple interdisciplinary teams to develop a comprehensive
program to comply with the USP <800> Standards, yet infusion nurses in the cancer center have
not been involved and are unfamiliar with the new mandatory safe-handling requirements. A
representative from the Cancer Center will be included in future discussions and planning
phases. Personal protective equipment and supplies, such as gloves, gowns, facemasks, eye
protection, and respiratory devices, should be tested by nurses for comfort and ease of use.
Comfort, choice, and ease of use may be secondary to organizations who must control expenses.
Current budgets for the Cancer Center and AIC are under review, and additional funds will be
requested to ensure sufficient PPE is allotted to the AIC.
Another limitation is that the DNP project will be conducted in a single center, and even
though response rates for the self-assessment survey include the total AIC nursing population,
the overall sample size may be too small compared to larger AICs. A multi-center approach
would increase the value of the findings related to PPE adherence in AICs. In addition, it is
possible the nurses could be evaluated multiple times on different days by different observers.
The registered nurses who complete the self-assessments may be different from the ones who are
being observed each day.
Furthermore, environmental wipe sampling and staff health monitoring will be costly, yet
vitally important for all working in high exposure risk areas. The organization is self-insured for
workers compensation and has increased efforts to proactively address additional costs due to
employee adverse health events following exposure incidents through staff medical monitoring,
HD education and training. Funding for the project should be added to the 2020 budget
beginning in July 2019 to make additional preparations for USP <800> compliance by December
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1, 2019. However, budget considerations in the Spring of 2019 require an additional 20%
increase to cover expenses for PPE, waste disposal bins, sharps disposal devices, increased waste
disposal services, and HD environmental monitoring supplies until the new budget has been
approved.
Conclusions
Maintaining supportive best practices with HD administration and PPE provides a
message of commitment to staff and the public that safety concerns are paramount. Similar to
interventions for handwashing to prevent contamination, patients should be encouraged to speak
up when they view a situation where PPE should be utilized. Critical components of sustained
success are staff education and ownership of the required changes relevant to PPE use, peerperformance monitoring, leadership support, prioritization of workload, and continuous
monitoring and feedback regarding performance. The fact that all involved in patient care have a
responsibility to maintain the standard is well-established and accepted. Current data are limited
on the long-term effects of HD exposure; yet, the literature concludes that there is no welldefined safe level of exposure. Control systems, similar to individual staff radiation exposure
tags that monitor monthly levels in the field of radiology, are currently unavailable. Enforceable
regulations to protect workers must be monitored by state, federal, and accreditation
organizations to increase compliance and to sustain pressure on healthcare providers to
consistently provide HD protections.
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Appendix A: Evidence Table
Citation
Bohlandt et al.
(2017)

Boiano et al.
(2014)

Statistical Tools

Data Collected

Wipe samples/surface
monitoring, urine collection,
questionnaire on household.
Analyses carried out under
strict internal and external
quality assurances;
SPSS Version 21;
Spearman rank correlation
test/Mann-Whitney-U test for
independent variables.

Setting: Patient homes s/p
chemo admin
Sample:
1) 265 wipe samples/13
homes at two times after
chemo from common
household surfaces.
2) 62 urine samples from
patients and family members
on three days.
3) Drugs analyzed:
cyclophosphamide (CP), 5fluorouracil (5-FU), and
platinum (PT).
Time Frame: Up to 4 days
Results: Substantial
contamination on every
surface type (PT: 0.02-42.5
pg/cm2; 5-FU: ND
98.3pg/cm2; CP: ND-283.3
pg/cm2)
Setting: NIOSH web-based
survey
Sample: 98% of 2,069
respondents were nurses
Time Frame: Jan 28 to Mar
29, 2011
Results: The survey results
show deficiencies related to
the lack/infrequency of
training, awareness of

NIOSH Survey of Healthcare
Workers (an anonymous,
multi-module, web-based
survey), SAS 9.3 to analyze
data.

Quality of Evidence
Level: I
Quality: A
Limitations:
Spot samples, both wipe and
urine samples, only reflect the
current situation and that
probably different results may
have been found when
performing continuous urine
collection.

Highlights from Article
Aim: To evaluate the surface
contamination and the
potential uptake of
antineoplastic drug residues
by family members at home
of chemotherapy patients.
Exposure was evident in
patient homes on various
surfaces. Adequate hygienic
and protective measures are
necessary to minimize the
exposure risk for cohabitants.
Elevated levels in patient’s
urine more than 48 hours, no
drug residues in family
members’ urine.

Level: I
Quality: A
Limitations:
Survey was targeted to
members of professional
practice organizations and are
not generalizable to all
healthcare workers or to all
members of each of the

Authoritative guidelines are
not being universally
followed.
Activities that increased
exposure risk per
respondents, included: failure
to wear nonabsorbent gown
with closed front and tight
cuffs (42%), IV tubing
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employer procedures, and
awareness of national safehandling guidelines.
Multiple breaches in safe
work practices (CSTDs, luerlick fittings, needleless
system).

Callahan et al.
(2016)

Descriptive, cross-sectional
correlational design study.
Survey Hazardous Drug
Handling Questionnaire.
Data were analyzed using
descriptive statistics and
multiple regression analysis.
(main research variables:
exposure knowledge, selfefficacy, perceived risk,
interpersonal influences, and
workplace safety climate).
Survey Monkey software
database, SPSS V21.0,
Spearman’s correlation
coefficients,
Wilcoxon rank sum tests.

Setting: The National
Institutes of Health Clinical
Center in Bethesda, Maryland
Sample: 196 eligible/115 RNs
working on high-volume HD
administration units.
Time Frame:
Results: Total mean HD
precaution use proved highest
during HD administration and
lowest for handling excreta at
48 hours. Average patients
per day significantly
influenced total HD
precaution: more precaution
use with fewer patients
assigned.

participating professional
organizations.
The survey was only
available to members with
email addresses and internet
access.

Level: II
Quality: A
Limitations:
Self-report survey conducted
in one specialized research
hospital and cannot be
generalized without
replication to other settings.
Nurses were required to
attend formal training to
administer chemo and
biotherapy and gain oncology
nursing certification

primed with antineoplastic
drug (6%) or by pharmacy
(12%), potentially
contaminated clothing taken
home (12%), gloves (12%),
lack of hazard awareness
training (4%).
Most common reason for not
wearing gloves or gowns was
“skin exposure was minimal,”
but respondents reported skin
contact during handling and
administration.
Purpose: To identify factors
associated with oncology
nurses’ use of HD safehandling precautions in
inpatient clinical research
units.
Data were analyzed using
descriptive statistics and
multiple regression analysis.
(main research variables:
exposure knowledge, selfefficacy, perceived risk,
interpersonal influences, and
workplace safety climate).
Conclusions: Despite high
exposure knowledge, barriers
to PPE use and conflict of
interest may contribute to
reduced adoption of personal
protective practices among
oncology nurses.
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Colvin et al.
(2016).

Connor et al.
(2014)

Prospective, mixed-methods
study to compare objective
and subjective nurse
behavior, micro-ethnography
and questionnaires.

Literature search using the
following databases:
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Setting: Cleveland Clinic
Sample: 22 cases of chemo
handling observed, 12 of 33
nurses completed
questionnaires.
Time Frame: Jan 2012 to Mar
2013
Results: Data analysis
involved describing the nurse
skill checklist frequencies and
self-assessment of RN
characteristics using medians
and quartiles of counts and
percentages for all categorical
variables.

Setting: Literature review

Level: III
Quality: A
Limitations:
Study conducted in a single
center, and the sample size
was small.
Sample size for nurse
observations was small.
Lack of uniformity in
assessment item working
could have led to differences
in reported frequencies in
adherence to PPE
recommendations. One nurse
may have been observed
more than once on different
days. Nurses observed had
two or more years nursing
experience in oncology
nursing and may not have
been well matched in the
group comparisons.
Analyses were based on
group findings; no
correlations were noted
between observed behaviors
and self-assessment by
individual nurses.
Level: III
Quality: A

Hospitals and unit-specific
factors captured by the
predictor variables could
contribute to institutional HD
policy.
The aims of the pilot study
were to examine actual and
subjective ambulatory
oncology nurse adherence to
chemotherapy safe-handling
with NIOSH PPE and
hospital policy exposure
controls.
Consistent adherence to
practice expectations may
require more than an annual
competency assessment.
Chemotherapy exposure is a
team concern in that one
healthcare clinician can
follow all policies, yet still be
exposed to chemo if others
fail to do so.

Antineoplastic drugs are
highly toxic in patients
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•
•
•
•
•
•
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Connor et al.
(2016)

Canadian
CINAHL
CISILO
DTIC, Embase
Healthy and safety
abstracts
HSELine
NIOSHTIC-2
OSHLine
PubMed, Risk
abstracts
Toxicology Abstracts
Toxline, Web of
Science
WorldCat

Not stated
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Sample: 18 peer-reviewed,
English language publications
of occupational exposure and
reproductive outcomes
studies.
Time Frame: Literature
review completed 1980 to
February 2014
Results: While effect sizes
varied with study size and
population, occupational
exposure to antineoplastic
drugs appear to raise the risk
of both congenital
malformations and
miscarriage. Studies of
infertility and time-topregnancy also suggested risk
for sub-fertility.
Measurement of surface
contamination is the best
indicator of the level of
environmental contamination
in areas where Ads are
prepared, administered to
patients, or otherwise handled
(such as receiving areas,
transit routes throughout the
facility, and waste storage
areas).
The odds ratio of adjusted
models ranged from 1.36
(95% CI, 0.59-3.14) to 5.1
(95% CI, 1.1 -23.6)
Setting: Article review by
experts at NIOSH

Limitations:
Small sample sizes
5/8 studies had 10 or fewer
exposed cases. All studies
had fewer than 20 exposed
cases. Limited ability to
adjust for confounding; the
need to group anomalies that
had different etiologies and
wide confidence intervals,
which reflect poor statistical
power.

Level: III
Quality: A

receiving treatment and
adverse reproductive effects
have been well documented
in these patients. HCW with
chronic, low-level
occupational exposure to
these drugs also appear to
have an increased risk of
adverse reproductive
outcomes. Additional
precautions to prevent
exposure should be
considered (NIOSH).
Some studies have shown an
association between surface
contamination and worker
exposure.
For pregnant women, the
window of risk begins one
month before conception and
lasts through pregnancy (most
vulnerable in first trimester).
Breast milk is affected by HD
exposure.
A man’s sperm is vulnerable
to HDs from as early as 2
months before conception.

The purpose of the article was
to review published studies of
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Crickman &
Finnell (2016)

Databases searched:
• PubMed
• CINAHL
• Cochrane Library
• EMBASE
English language
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Sample: not stated
Time Frame: not stated
Results:
A comprehensive safehandling program for ADs
may utilize wipe sampling as
a screening tool to evaluate
the environmental
contamination and strive to
reduce contamination levels,
as much as possible, using the
industrial hygiene hierarchy
of controls.
Setting: Systematic literature
review
Sample: 29 publications met
final review criteria
Time Frame: 1979 to 2014
Results: 5 major strategies
identified (engineering
controls, PPE, medical and
environmental monitoring,
hazard identification, need for
comprehensive HD control
program that includes
education and training for
HCWs).
Transparency in every step in
the chain of custody is
needed. Clear signs or labels,
including electronic
identifiers, and clear
instructions that prompt what
to do next are needed.

Wipe sample area
recommendations:
Nurses’ station storage area
for IV bags
Countertops
Furniture in patient rooms
Infusion pump
Door handles, door knobs,
other high-touch areas
Computer keyboard/mouse
Floor in patient room
Floor in restroom
Level: III
Quality: A

wipe sampling for
antineoplastic and other HDs,
to summarize the methods in
use by various organizations
and researchers, and to
provide some basic guidance
for conducting surface wipe
sampling for these drugs in
healthcare settings.

The systematic review was
conducted to identify
evidence-based strategies for
protecting all HCWs, from
those involved in handling
packaged HDs to those who
dispose of body fluids of
individuals taking these
medications.
One problem with wipe
testing is that there is no
minimum acceptable
exposure level for
chemotherapy or other HDs.
Testing workers’ urine/blood
samples may be difficult to
operationalize across large
healthcare systems. Financial
and ethical implications must
be considered, specifically
with how to counsel staff
members with positive results
of urine or blood samples.
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DeJoy et al.
(2017)

Data came from the 2011
NIOSH Health and Safety
Practices Survey of
Healthcare Workers, an
anonymous, multi-module,
web-based survey.
Statistical analyses were
performed using SAS 9.4
software in three stages: (1)
descriptive analyses, (2)
factor analysis of safety
perception, and (3)
psychometric analyses.

40

Setting: Online survey
Sample: Nurses (N=1,814)
who had administered IV
HDs in the 7 calendar days
prior to the survey and whose
employer was either a
hospital or ambulatory
healthcare center.
Time frame: Survey was
available for 8 weeks.
Results: The study showed
lower likelihoods of exposure
when staffing and resources
were adequate and when
orders and doses were
consistently verified by two
nurses.

Level: III
Quality: A
Limitations:
• Cross-sectional study limits
the ability to make causal
interpretations.
• Survey respondents were
solicited from membership
rolls of professional
organizations and may not
represent all nurses who
administer HDs.
• The sample was limited to
nurses working in the U.S.
• Data collected were
analyzed at the individual
level.
• The collected data were
self-reported/could not
eliminate bias.

Barriers such as
understaffing, the physical
layout of a unit, and time
constraints can negatively
impact adherence.
Purpose/Objectives: To
examine predictors of the use
of PPE and engineering
controls and adverse events
involving IV HDs in a
relatively large and diverse
sample of nurses.
The study examined the
effects of pertinent
organization safety practices
and perceived safety climate
on the use of PPE,
engineering controls, and
adverse events (spill/leak or
skin contact) involving liquid
antineoplastic drugs.
14% of nurses reported an
adverse event.
Results point to the value of
implementing a
comprehensive health and
safety program that uses
available hazard controls and
effectively communicates and
demonstrates the importance
of safe-handling practices.
Such actions also contribute
to creating a positive safety
climate.
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Having an adequate
knowledge of risks does not
automatically produce
commensurate precautionary
action.

Friese et al.
(2019)

Methods & variables:
1. Revised Drug Handling
Questionnaire (Martin &
Larson, 2003; Polovich &
Clark, 2012)
2. Practice Environment Scale
(Friese, 2012).
3. Safety Organizing Scale
(Vogus & Sutcliffe, 2006)
4. The authors measured
knowledge of HD handling
using a team-generated, pilottested, 10-item questionnaire.
5. Occupational Dermal
Survey to measure perceived
risk (Geer, Curbow, Anna,
Lees, & Buckley, 2006).
In a cluster randomized
controlled trial, 136 nurses in

Setting: 12 ambulatory
oncology settings in the
United States. 15 sites were
eligible, but 3 declined
participating in study
12 sites were randomized
6 sites control arm
6 sites allocated to
intervention.
Sample: 396 nurses, 257 of
who completed baseline and
primary endpoint surveys.
Time frame: March 2015 to
March 2017
Results: Control and
intervention sites had
suboptimal PPE use before
and after the intervention. No

Level: I
Quality: A
Limitations:
First, the study took place in a
convenience sample of
academic health centers with
high-volume cancer
programs. (Results may not
generalize to smaller or
community-based oncology
settings).
Second, the calculated
reliability of the outcome
measure in the current sample
was relatively low (0.46 for
the 3-item measure and 0.5
for the 5-item measure
considered in the sensitivity
analysis).

PPE use was lower among
nurses working in ambulatory
infusion centers and be
caused by less formalized
safety programs and perhaps
less direct supervision of
those administering HDs.
Both of these factors could
lead to diminished adherence.
Purpose/Objectives: To
evaluate whether a web-based
intervention improved PPE
use among oncology nurses
who handle hazardous drugs.
Findings: It is clear that
education and engagement of
nursing personnel is not
sufficient to improve PPE use
– systematic approaches may
result in improved practice.
Conclusion: Despite four
decades of research, current
use of PPE remains
suboptimal in ambulatory
oncology settings. A theoryinformed, web-based
educational intervention to
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control settings received a
one-hour educational module
on PPE use with quarterly
reminders, and 121 nurses in
treatment settings received
the control intervention plus
tailored messages to address
perceived barriers and
quarterly data gathered in HD
spills across all study settings.
The primary outcome was
nurse-reported PPE use.
The primary outcome was
PPE use, as measured by the
previously published Revised
Drug Handling Questionnaire
(Martin & Larson, 2003;
Polovich & Clark, 2012).
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significant differences were
observed in PPE-use
knowledge or perceived
barriers. Participants reported
high satisfaction with the
study experience.

RNs failed to improve PPE
use in the ambulatory
oncology setting.
A multi-faceted strategy
(equipment changes,
standardized policies,
educational efforts, and
leadership support) across
multiple levels (units,
hospitals, and health systems,
and professional
organizations) may be
required to improve
adherence to HD-handling
guidance.
Implications for Nursing:
HD exposure confers notable
health risks to healthcare
workers. To improve HD
handling, occupational
healthcare workers, health
systems, and professional
organizations should consider
coordinated efforts to
implement policy and
practice changes.
Other Data of Interest:
Future research efforts would
benefit from development and
testing of novel measures of
PPE use and evaluation of
optimal measurement times
after delivering educational
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interventions and delivering
study reminders.

He et al. (2017)

1.Cross-sectional, multi-state
mailed survey to ONS
members (N=654)
Tool: Revised Hazardous
Drug Handling Questionnaire
(Martin & Larson, 2003;
Polovich & Clark, 2012)
2. Bivariate and multivariable
regression analyses
3. Covariates: nursing
workloads, nurses’ practice
environments, and barriers to
PPE use
4. Dillman’s total design
method to maximize response
rates (personalized cover
letters, $40 cash incentives,
three monthly reminders to
non-responders)
5. Safety Organizing Scale to
measure collective behaviors
performed by employees in
high-reliability organizations

Setting: Ambulatory
oncology practices in CA,
GA, and MI
Sample: 252 ONS members
who administer hazardous
drugs
Time frame: February to
September 2014
Results:
437 nurses completed surveys
(67% response). Final
analytical sample (n=252),
97% women, 79% 43 years or
older, 75% with at least 6
years of nursing experience,
and 96% worked in outpatient
oncology settings. The
sample mean for the PPE-use
score was 2.4 (SD=1) out of a
maximum possible score of 5.

Level: II
Quality: A
Limitations:
The internal reliability of the
dependent variable – the PPEuse scale – was lower in the
current sample (0.61) than
previously reported (Geer et
al., 2006).
The distribution of various
PPE (included on the PPEuse scale) had a bimodal
pattern; many respondents
reported either using PPE
very frequently or never.
Other limitations included a
varying number of
respondents per practice (112 nurses) and missing data.
Roughly a third of practices
had only one nurse informant.
These limitations are
somewhat offset by the large
sample size, high response,
rate, and geographic
diversity.

Purpose/Objectives: To
examine patterns and
organizational correlates of
PPE use and hazardous drug
spills.
Findings: 26% reported
recent drug spill, 90% wore
only 1 pair of chemotherapytested gloves. PPE use was
associated with increased
nurse participation in practice
affairs, non-private
ownership, increased nursing
workloads, and fewer barriers
to PPE use. Spills were
associated with significantly
less favorable manager
leadership and support and
higher workloads.
Conclusion: Drug spills occur
in ambulatory settings. PPE
use remains low, and barriers
to PPE use persist. Higher
workloads are associated with
more drug spills. As nursing
workloads increased by one
patient, the odds of HD spills
increased by 3% (OR=1.03,
95% CI [1.01-1.06], p=0.01).
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Implications for Nursing:
Managers should monitor and
correct aberrant workloads
and ensure that PPE is
available and that staff are
trained.
Other Data of Interest:
The study findings
underscore the need to
improve individual adherence
through modifiable
administrative controls (e.g.,
commitments to safety
culture, improved nurse
practice environments,
thoughtful attention to nurse
workloads, deployment of
engineering controls).

Hennessy &
Dynan (2014)

Framework for the Model for
Improvement (Langley,
Moen, Nolan, Norman, &
Provost, 1996), a continuous
process of tests of change,
performance measurement,
and feedback was put into
place to improve
performance.
Monthly audits with PPE
Observation Tool created by
Dana Farber educators.

Setting: Dana Farber Cancer
Institute
Sample: Infusion nurses in
ambulatory care
Time Frame: 2009-2014
Results: Previous compliance
rates 30%-40%
Key components of the
sustained success of this
initiative are staff education
and ownership of the required
changes, peer-performance
monitoring, leadership
support and prioritization of
the work, staff involvement in
product review and selection

Level: III
Quality: A

A program was developed
that incorporated not only
monitoring and reporting
compliance of the use of PPE,
but also engaged the staff in
audit and reporting activities.
Compliance rates improved
dramatically over time and
have remained at high levels.
The goal was to improve
compliance with established
standards and hospital policy
regarding PPE use by nurses
administering chemo in the
outpatient setting.
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Hon et al.
(2014)

Kang et al.
(2017)

Wipe samples analyzed for
cyclophosphamide (CP).
High-performance liquid
chromatography-tandem mass
spectrometry.
Active recruitment of
participants via letter of
invitation or telephone by
members of research team.
On-site surveys and selfadministration questionnaire.

Observational, descriptive
study in 4 parts: a simulation
observation, a survey (for
both clinical and sim
participants), and a follow-up
evaluation simulation.
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of the PPE, and continuous
monitoring and feedback
regarding performance.
Setting: 5 hospitals and 1
cancer treatment facility
Sample: 115 participants/110
supplied duplicate hand wipe
sampling. Staff working in
the process of flow of drug
within a facility from initial
delivery to waste disposal
(8 groups of workers
identified).
Time Frame: not stated
Results: 225 wipe
samples/20% (n=44) were
above the limit of detection
(LOD) of 0.36ng per wipe.
Average concentration per
wipe 22.8ng per wipe. (SD
1.98).

Setting: University of
Pittsburgh
Sample: 82 HCP, 65 HCP
(72.93%; including 3 HCP
who participated in the
clinical observation). 97%
had at least 1 instance of
contamination during the PPE
doffing process in 2 sim
sessions with a simple set and
a full-body set. For 130

Level: I
Quality: A
Limitations:
Unable to recruit
housekeepers into study
because the contract company
that employs housekeepers
declined to participate.
The findings are only
representative of the point in
time when samples were
collected.
Samples were based on
convenience sampling, which
allowed assessment of
exposure throughout the day,
but does not allow
comparison to task-based
exposure levels.
Level:
Quality:
Limitations:
High likelihood of Hawthorne
effect. Because convenience
sample of study participants
and PPE items from one
health care system were
adopted, these findings may

The purpose of the study was
to determine the dermal
contamination levels of
healthcare employees
working throughout the
hospital and to identify
factors that may influence
dermal contamination.
All worker categories had
some level of dermal
exposure. Highest level of
dermal exposure was in
administration units who
were not responsible for drug
administration (volunteers,
oncologist, aide, dietician).
Regardless of whether or not
a worker received safe drug
handling training, the
proportion of samples above
LOD was the same.
Very little is known about
how healthcare personnel
actually use PPE.
Evidence shows that
traditional learning methods
(e.g., watching educational
videos, learning PPE
guidelines) are inferior to
immersive learning methods,
including active learner
involvement using
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simulations, the
contamination rate was 79%
(n=103)
Time Frame: August 31September, 2015
Results:

Lawson et al.
(2019)

Self-report questionnaire for
pregnant nurses (within first
20 weeks) and non-pregnant
nurses (within the last
month).
Baseline NHS3 questionnaire.

Setting: Online study
Sample: 40,000 nurses
participating in the Nurses’
Health Study born on or after
January. 1, 1965
Time Frame: Started in 2010
and is ongoing
Results:
12% of non-pregnant
nurses/9% pregnant nurses
indicated they never wore
gloves with HD admin,
42%/38% never used a gown,
32% who crushed HD pills
did not wear gloves.
Mean age/non-pregnant = 37
years (SD 7.26)
Mean age/pregnant = 29.5
years (SD 4.05).

not be generalizable to other
clinical settings.
Camera lens and lighting may
not have captured all
contamination.

simulations that include
feedback on performance.
Contamination breaches
appear to be associated with
poor HCP PPE techniques,
knowledge deficits, and
behavior flaws.
The study emphasized the
need for refining PPE
protocols based on further
scientific evidence,
reinforcing PPE training
using innovative methods,
improving and standardizing
PPE equipment for targeting
HCP optimal use.
Level: II
The purpose of the study
Quality: A
assessed glove and gown use
by female pregnant and nonLimitations:
pregnant nurses who
Did not collect info on the use administer antineoplastic
of double versus single
drugs in the U.S. and Canada.
gloves, engineering controls,
training of safe-handling
Findings underscore the need
practices, and reasons or
for further training and
barriers for not following
education to ensure that both
safe-handling
employers and nurses
recommendations.
understand the risks involved
No information on nurse
and know which precautions
specialties of respondents.
will minimize such
No info on facility type or
exposures. Adequate time
size, which might affect
must be allowed for worker to
training personnel.
handle these drugs safely.
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Yuki et al.
(2013)

Urine and wipe samples from
patient and family members
inside homes.
Gas chromatography in
tandem with mass
spectroscopy-mass
spectroscopy or by highperformance liquid
chromatography with
ultraviolet-light detection.
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Setting: 3 patient homes
Sample:
Time Frame:
Results: 35 and 16 urine
samples were collected from
the three patients and their
family members. Drugs were
detected in all samples.
Cyclophosphamide (CP) in 8
of 12 samples 5-FU exposure
below the limit of detection.

Level: I
Quality: A
Limitations:
Sample size small

Purpose: To measure the
urinary excretion of Ads of
three patients during 48 h
after the admin of
cyclophosphamide (2
patients) and 5-FU (2
patients)
Home exposure was
demonstrated. Findings
indicate the importance of
strict precautions by the
members of treated cancer
patients, as well as healthcare
workers, to reduce exposure
to Ads.

USP <800> AND THE PPE PROJECT
Appendix B: Commission on Cancer Program Standard 4.8
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Appendix C: Basic Steps of Compliance Flow Chart
Step 1: Appointment the QIC and determine the required # of studies to complete.

Step 2:Identify the
problem

Step 3: Define study
methodology and
criteria for evaluation

Step 4: Conduct the
study as planned

Step 5: Analyze data:
perpare summary of
findings

Step 6: Compare data
results with national
benchmark/guidelines

Step 7: Design action
plan based on results
and FU to monitor
actions implemented

Step 8: QIC presents
study results to cancer
committee and
report/discussion is
documented in
minutes
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Appendix D: Signed Statement of Non-Research Determination
Student Name: Cynthia D. Huff
Title of Project: USP <800> Compliance: A Hazardous Drug Safe-Handling PPE
Toolkit for Infusion Nurses
Brief Description of Project: Hazardous drug (HD) residues pose a real threat to the
health of staff, patients and families, and the environment when uncontrolled or
mismanaged, especially in Cancer Centers (Hon, Teschke, Shen, Demers, & Venners,
20150. Lack of diligent organizational and personal responsibility, and oversight in HD
management have caused irreversible harm in some cases, and are well documented
(Connor, Lawson, Polovich, & McDiarmid, 2014; Yuki, Sekine, Takase, Ishida, &
Sessink, 2013). Scientific evidence has demonstrated that harmful residues can
contaminate commonly shared surfaces where HDs are administered, and patients may
expose family members, pets, and their homes to residues for several days to weeks after
chemotherapy treatment (Bohlandt, Sverdel, & Schierl, 2017; Yuki, et al., 2013).
Healthcare organizations are preparing for the implementation of USP <800> (United
States Pharmacopeial Chapter 800: Hazardous Drugs-Handling in Health Care Settings
which imposes strict regulatory standards intended to protect health care workers from
HD exposure beginning December 1, 2019. As USP <800> changes how HDs are
handled, timely education and acceptance from health care personnel, especially
pharmacists and nurses, will drive the long-anticipated worker protections (Andrews &
Dill, 2018). The purpose of an Ambulatory Care Hazardous Drug Safe-Handling PPE
Toolkit for Infusion Nurses is to provide a resource toolkit that will improve nurses’
adherence to personal protective equipment (PPE) use, increase compliance with USP
<800> Standards, and adhere to hospital policies and procedures for safe-handling.
Better risk education is needed to ensure employers and health care workers are fully
aware of the processes required to minimize exposure to these toxic drugs (Boiano,
Steege, & Sweeney, 2014). There are six steps in the safe handling process for HDs: (1)
Transport, (2) Receipt, (3) Storage, (4) Preparation, (5) Administration, and (6) Disposal
of contaminated waste.
A) Aim Statement: By February 1, 2020, develop, implement, and evaluate a HD
resource toolkit to improve adherence to personal protective equipment (PPE) use to 90%
or higher with hazardous drug administration and with current hospital and USP <800>
policies and procedures.
B) Description of Interventions:
1. September, 2019 – Confidential observations of infusion nurses preparing,
administering, and discarding HD waste will be completed by the DNP student (to
determine the baseline level of adherence using an established tool called the “PPE
Observation Tool” (Hennessy & Dynan, 2014). A survey to obtain nurses’ selfassessments of adherence to policies and USP <800> will be provided to the AIC
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nurses via Qualtrics.
2. October, 2019 – An expert panel will introduce the Hazardous Drug SafeHandling PPE Toolkit to staff and bring awareness of the health risks with HD
exposure, and explore barriers for self-adherence in the practice environment.
Ambulatory Infusion Center (AIC) nurses will attend a two-hour skills session to
introduce them to the proper donning and doffing of PPE and the policies and
procedure changes related to mandatory requirements imposed by USP <800>.
3. November, 2019 – Individual nurse observations will be performed to assess for
PPE adherence and compared to the self-assessment survey results to reinforce USP
<800> standards and hospital policies and procedures for safe-handling and protections
using the “Safe-Handling Adherence Between Observation and Self-Assessment tool.”
A “Hazardous Drug Administration Safe Handling Checklist” (Peer-to-Peer Feedback
tool) will be utilized to educate and reinforce goal 90% PPE compliance for all nurses
handling HDs (Polovich & Olsen, 2017).
4. December, 2019 – Data will be collected pre-and-post intervention, analyzed, and
displayed for staff on the performance dashboard as a quality improvement project.
5. January and February, 2020 – DNP student will present results to the respective
committees and enter the results in the Cancer Committee’s minutes to fulfill the COC
Standard 4.8 requirements.
C) How will this intervention change practice?
The Hazardous Drug Safe-Handling PPE Toolkit intervention is expected to improve
nurses’ access to USP <800> PPE requirements and improve adherence and
compliance with the organization’s policy and procedures for HD safe-handling.
D) Outcome measurements:
1. Monthly peer-to-peer audit tool and real-time feedback indicate 90% or higher
adherence and compliance with PPE use during hazardous drug administration
processes.
2. Pre-and-post intervention analysis posted on performance dashboard for staff
review and comments.
3. 100% compliance with USP <800> PPE expectations during hazardous drug
administration as evidenced by internal audit from oncology infusion nurses, quality
and risk management department managers, and nursing education audits annually.
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To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the
criteria outlined in federal guidelines will be used: (http://answers.hhs.gov/ohrp/categories/1569)

x This project meets the guidelines for an Evidence-based Change in Practice Project as
outlined in the Project Checklist (attached). Student may proceed with implementation.

☐This project involves research with human subjects and must be submitted for IRB approval
before project activity can commence.
Comments:
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST *
Instructions: Answer YES or NO to each of the following statements:
Project Title:
USP <800> Compliance: Hazardous Drug Safe-Handling Toolkit for Infusion
Nurses
The aim of the project is to improve the process or delivery of care with
established/ accepted standards, or to implement evidence-based change. There is
no intention of using the data for research purposes.
The specific aim is to improve performance on a specific service or program and is
a part of usual care. ALL participants will receive standard of care.
The project is NOT designed to follow a research design, e.g., hypothesis testing
or group comparison, randomization, control groups, prospective comparison
groups, cross-sectional, case control). The project does NOT follow a protocol that
overrides clinical decision-making.
The project involves implementation of established and tested quality standards
and/or systematic monitoring, assessment or evaluation of the organization to
ensure that existing quality standards are being met. The project does NOT
develop paradigms or untested methods or new untested standards.
The project involves implementation of care practices and interventions that are
consensus-based or evidence-based. The project does NOT seek to test an
intervention that is beyond current science and experience.
The project is conducted by staff where the project will take place and involves
staff who are working at an agency that has an agreement with USF SONHP.
The project has NO funding from federal agencies or research-focused
organizations and is not receiving funding for implementation research.
The agency or clinical practice unit agrees that this is a project that will be
implemented to improve the process or delivery of care, i.e., not a personal
research project that is dependent upon the voluntary participation of colleagues,
students and/ or patients.
If there is an intent to, or possibility of publishing your work, you and supervising
faculty and the agency oversight committee are comfortable with the following
statement in your methods section: “This project was undertaken as an Evidencebased change of practice project at X hospital or agency and as such was not
formally supervised by the Institutional Review Board.”

YES

X

X
X

X

X

X
X
X

X

NO
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ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an
Evidence-based activity that does NOT meet the definition of research. IRB review is not
required. Keep a copy of this checklist in your files. If the answer to ANY of these questions
is NO, you must submit for IRB approval.
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human
Research Committee, Partners Health System, Boston, MA.
STUDENT NAME (Please print):
Cynthia Huff
Signature of Student:
______________________________________________________DATE____________

SUPERVISING FACULTY MEMBER (CHAIR) NAME (Please print):
________________________________________________________________________
Signature of Supervising Faculty Member (Chair):
______________________________________________________DATE____________
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Appendix E: Gap Analysis
1.
2.
3.
4.
5.
6.

7.
8.

The physical layout of the treatment areas lend difficulty with hazardous drug (HD)
administration.
The AIC is not set up for moderate HD disposal; there are gaps in pharmaceutical waste
management (i.e. PPE).
Policies and procedures do not reflect USP <800> requirements for HD processes and
require modifications for AIC compliance with PPE management and waste disposal.
The cost impact for meeting the USP <800> Standards are unknown because the nurses
in the AIC are not wearing required PPE except for one pair of nitrile gloves.
There is no standard work for HD administration in the AIC.
There are gaps in pharmaceutical delivery of HDs to the nurses (need to be delivered in
specific HD bins and stored in cabinets in the medication rooms, not on countertops in
patient areas).
There is no system-defined comprehensive list of HDs for the AIC (NIOSH List of
Hazardous Drugs is the default), and there is no risk assessment for all HDs.
No annual PPE training or learning modules for HD administration.

9.

There are space limitations within the treatment area for donning and doffing PPE in the
designated patient threshold areas.
10. Adherence and compliance with PPE have been ignored for several years in the AIC, and
nurses’ beliefs and attitudes that exposure risks are minimal and do not warrant changing
behavior with HD administration.
11. Scheduling demands and workload pressures do not reflect the appropriate acuity levels
of patient appointment times and unique situations.
12. There are inconsistent HD labeling on medications delivered by the pharmacy.
13. Tools needed to assess for PPE compliance, such as observation tools or Standard work
for “HD Safe Handling” are unavailable in the AIC.
14. No staff champions to promote best practice with PPE use.
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Appendix F: Gantt Chart
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Appendix G: Work Breakdown Structure
LEVEL 1
1 PPE Toolkit
Implementation
in Ambulatory
Care

LEVEL 2
1.1 Initiation

LEVEL 3
1.1.1 Evaluation and Recommendations
1.1.2 Develop Project Charter
1.1.3 Deliverable: Submit Project Charter
1.1.4 USP <800> Committee Reviews Project Charter
1.1.5 Project Charter Signed/Approved

1.2 Planning

1.2.1 Create Preliminary Scope Statement
1.2.2 Determine Project Team
1.2.3 Project Team Kickoff Meeting
1.2.4 Develop Project Plan
1.2.5 Submit Project Plan
1.2.6 Milestone: Project Plan Approval

1.3 Execution

1.3.1 Project Kickoff Meeting
1.3.2 Verify & Validate USP <800> PPE Requirements
1.3.3 Develop/Organize HD PPE Toolkit
1.3.4 Decide on Specific Type/Amount of PPE per unit
1.3.5 Testing Phase in Ambulatory Infusion Center
(AIC)
1.3.6 Completed Toolkit Introduced in AIC
1.3.7 Staff Training
1.3.8 Go Live

1.4 Control

1.4.1 Project Management
1.4.2 Project Status Meetings
1.4.3 Risk Management
1.4.4 Update Project Management Plan

1.5 Closeout

1.5.1 Audit Procurement
1.5.2 Document Lessons Learned
1.5.3 Update Files/Records
1.5.4 Gain Formal Acceptance
1.5.5 Archive Files/Documents
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Appendix H: Work Breakdown Structure Dictionary
Level
1

WBS
Code
1

Element Name

Definition

2
3

1.1
1.1.1

Personal Protective Equipment
(PPE) Toolkit Implementation in
Ambulatory Care
Initiation
Evaluation and Recommendations

All work to implement the new toolkit in
Ambulatory Care Setting.

3

1.1.2

Develop Project Charter

3

1.1.3

Deliverable: Submit Project Charter

3

1.1.4

3

1.1.5

USP <800> Committee Reviews
Project Charter
Project Charter Signed/Approved

2

1.2

Planning

3

1.2.1

Create Preliminary Scope Statement

3

1.2.2

Determine Project Team

3

1.2.3

Project Kickoff Meeting

3

1.2.4

Develop Project Plan

3

1.2.5

Submit Project Plan

3

1.2.6

Milestone: Project Plan Approval

2
3

1.3
1.3.1

Execution
Project Kickoff Meeting

3

1.3.2

Verify & Validate USP <800> PPE
Requirements

The work to initiate the project.
Working group to evaluate USP <800>
General Chapter PPE requirements and make
recommendations for the Ambulatory Care
Setting.
Project Manager to develop the Project
Charter.
Project Charter is delivered to USP <800>
Committee designee.
USP <800> Committee Reviews Project
Charter.
The USP <800> Committee signs the Project
Charter which authorizes the Project
Manager to move to the Planning Process.
The work for the planning process for the
project.
Project Manager creates a Preliminary Scope
Statement.
The Project Manager determines the project
team and requests the resources.
The planning process is officially started
with a project kickoff meeting which
includes the Project Manager, Project Team
and USP <800> Committee designee.
Under the direction of the Project manager,
the team develops the project plan.
Project Manager submits the project plan for
approval.
The project plan is approved and the Project
Manager has permission to proceed to
execute the project according to the project
plan.
Work involved to execute the project.
Project Manager conducts a formal kickoff
meeting with the project team, project
stakeholders, and USP <800> Committee
designee.
The original USP <800> General Chapter
requirements for personal protective
equipment (PPE) use with hazardous drug
agents is reviewed by the Project Manager
and team, then validated with the
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1.3.3

Develop/Organize HD PPE Toolkit

3

1.3.4

3

1.3.5

Decide on Specific Type/Amount of
PPE per Unit
Testing Phase in Ambulatory
Infusion Center

3

1.3.6

Completed PPE Toolkit introduced
into Ambulatory Infusion Center
setting

3

1.3.7

Staff Training

3

1.3.8

Go Live

2

1.4

Control

3
3
3

1.4.1
1.4.2
1.4.3

Project Management
Project Status Meetings
Risk Management

3

1.4.4

Update Project Management Plan

2
3

1.5
1.5.1

Closeout
Audit Procurement

3

1.5.2

Document Lessons Learned

3

1.5.3

Update Files/Records

3

1.5.4

Gain Formal Acceptance

3

1.5.5

Archive Files/Documents
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stakeholders. This is where additional
clarification may be needed.
The resources to design the new PPE toolkit
will be assembled.
The procurement of all PPE required for the
project.
Team creates a system for testing PPE
adherence and customizations of user
interfaces (Low, Moderate, High Risk) with
hazardous drug handling.
The actual PPE Toolkit is introduced into the
Ambulatory Infusion Center’s workflow
processes.
All staff are provided with a one-hour
training on donning and doffing of PPE.
Additionally, managers are provided with a
two-hour class to cover advanced reporting.
System goes live with all Ambulatory
Infusion Center (AIC) staff.
The work involved for the control process of
the project.
Overall project management for the project.
Weekly team status meetings.
Risk management efforts as defined in the
Risk Management Plan.
Project Manager updates the Project
Management Plan as the project progresses.
The work to close out the project.
An audit of all measurement tools and
management plans procured for the project,
ensure that all procured products are
accounted for and in the asset management
system.
Project Manager along with the project team
performs a “lessons learned” meeting and
documents the lessons learned from the
project.
All files, data, and adherence monitoring
tools are updated to reflect the completed
PPE Toolkit intervention.
The USP <800> Committee formally accepts
the project by signing the acceptance
document included in the project plan.
All project related files and documents are
formally archived.
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Appendix I: Work Breakdown Structure Glossary
Ambulatory Care
Settings

Hazardous Drug
Agents (HDs)

Level of Effort
Personal
Protective
Equipment (PPE)

PPE Toolkit

USP General
Chapter <800>
Scope (USP
<800>)

WBS Code
WBS Component
WBS Element

Work Package

Ambulatory Care refers to medical services performed on an outpatient basis,
without admission to a hospital or other facility. Ambulatory care is provided in
settings such as dialysis clinics, ambulatory infusion centers, ambulatory surgical
centers, hospital outpatient departments, and the offices of physicians and other
health professionals.
In pharmacology, hazardous drugs are drugs that are known to cause harm,
which may or may not include genotoxicity (the ability to cause a change or
mutation in genetic material). These drugs can be classified as antineoplastic,
cytotoxic agents, biologic agents, antiviral agents and immunosuppressive
agents. The NIOSH criteria include: carcinogenicity, teratogenicity, reproductive
toxicity, genotoxicity, organ toxicity at low doses, and drugs that mimic existing
drugs in structure or toxicity.
Level of Effort (LOE) is how much work is required to complete a task.
Personal protective equipment is protective clothing, headwear, goggles, gloves,
shoe covers, respirators, or other garments or equipment designed to protect the
wearer’s body from injury, infection, or exposure to hazardous agents. The
hazards addressed by protective equipment include physical, electrical, heat,
chemicals, biohazards, and airborne particulate matter.
A set of resources, interventions, and skills required to ensure staff adherence to
hazardous drug safe-handling and compliance with USP General Chapter <800>
requirements for PPE selection and use during transport, receivership, storage,
preparation, administration, and disposal.
Protects any worker in contact with hazardous drugs or the patient environment
and includes, but not limited to; pharmacists; technicians, nurses, physicians,
physician assistants, nurse practitioners, home health care, environmental
services workers, engineering, anyone entering a patient treatment area,
pharmacies, hospitals, and other healthcare institutions, patient treatment clinics,
physician practices, and the public.
A unique identifier assigned to each element in a Work Breakdown Structure for
the purpose of designating the elements hierarchical location within the WBS.
A component of a WBS which is located at any level. It can be a Work Package
or a WBS Element as there’s no restriction on what a WBS Component is.
A WBS element is a single WBS component and its associated attributes located
anywhere within a WBS. A WBS Element can contain work, or it can contain
other WBS Elements or Work Packages.
A Work Package is a deliverable or work component at the lowest level of its
WBS branch.
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Appendix J: Responsibility/Communication Matrix

Who
Cancer Committee Members
Assistant Unit Manager (AUM) AIC

What
Evaluation and Recommendations
Develop Project Charter

Assistant Unit Manager (AUM) AIC

Submit Project Charter

USP <800> Committee

USP <800> Committee Reviews Project
Charter
Project Charter Approved

USP <800> Committee/Cancer Committee
Cancer Committee
NPs/Pharmacy/AUM/Clinical Nurse Educator

Create Preliminary Scope Statement

Assistant Unit Manager

Determine Project Team

Project Charter Team Members

Project Team Kickoff Meeting

Assistant Unit Manager (AUM)

Submit Project Plan

Cancer Committee Members/ Executive
Director Cancer Center
USP <800> PPE Group

Milestone: Project Plan Approval

Clinical Nurse Educator
Pharmacy Department
USP <800> Committee Representative
Clinical Nurse Educator/ DNP Student (AUM
in AIC)

Verify & Validate USP <800> Requirements

Project Kickoff Meeting

Develop/Organize HD PPE Toolkit

How
Monthly at Cancer Committee meeting
Discuss project with leadership and ask for
recommendations of persons interested in
working on the PPE Project Team
Meet with interested people and gain buy-in
and have them help finalize the Charter and
AUM will send completed Charter to USP
<800. Committee
Present at USP <800> Committee meeting
and request approval from Project Sponsor
Committee will approve Charter and report
back to DNP team
Meeting with the group to discuss the needs
of the Cancer Center related to physician
practices/specialties
AUM to meet with interested persons and
select based on knowledge and skills related
to HD management and PPE knowledge
Arrange for meeting with group once Charter
has been approved via Skype or Zoom
sessions
AUM to assist team with project plan and
submit to USP<800> committee
Report back to Cancer Committee and gain
approval at next meeting
Notify PPE group of plans to set up meeting
by email and personal telephone calls
Check with OSHA, NIOSH, and USP<800>
Committee to confirm requirements for PPE
Review current evidence regarding toolkit
resources for HD PPE/select tools/request
permission from owners of tools to use
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Clinical Nurse Educator/ DNP Student
Relief Charge Nurses in AIC/Central Supply
Department

Decide on Specific Type/Amount of PPE per
unit

Clinical Nurse Educator/DNP Student

Testing Phase in AIC

NPs, Pharmacist, AUM

Confidential Observations in AIC

Oncology MD, NPs, Pharmacist, OCN Nurse,
Oncology Nurse Educator, AUM

Educational Intervention by Panel

DNP Student/ Clinical Nurse Educator

Completed Toolkit introduced in AIC

RN Staff in AIC

Staff Training-Peer-to-Peer Review

All Staff in AIC

Go Live

Request items used for PPE and bring to unit
for evaluation by nurses/discuss preferences
and select type and amount needed for test
phase
Preliminary testing with one RC to determine
feasibility of project and to demonstrate
“Observation of PPE Tool” purpose and
planned confidential use
Audits over 2 weeks at random intervals by
practitioners, pharmacy, and AUM during
routine rounding in AIC
Select panel of experts to introduce HD
education and need for PPE/invite to
informational meeting about project
Review final Tools for the toolkit and get
approval from Executive Director and expert
panel members to proceed with
printing/preparing for intervention
Provide inservice during monthly staff
meeting to teach use of peer-to-peer review
tool for PPE during administration
Use huddle boards, email, and text reminders
of Go Live with PPE date
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Appendix K: SWOT Analysis
Strengths
•
•
•
•
•

Expert Oncology Staff Resources
Infusion-Trained Chemotherapy Certified
RN Team
Supportive Leadership
Long-term Employees at the facility
committed to quality improvement at all
levels
Teamwork between various
divisions/pharmacy/physician offices and
ambulatory infusion centers through
focused workgroups

Weaknesses
•
•
•
•
•
•
•
•

Opportunities
•

•

•
•

Increase in demand for ambulatory
infusion services across the country
requires more oncology-infusion trained
nurses/may need to partner with nursing
schools to provide exposure/hiring pool
for future needs
Decrease the gap between leadership and
frontline infusion nurses to improve care
delivery and patient/nurse safety in the
AIC
Increase in the ageing population with
baby boomers at Medicare age
Increase all infusion nurses training on
chemotherapy/biotherapy/infusion
therapy for future growth needs

Room design and waste management not
practical for effective safe-handling
Employee and environmental surveillance
inconsistently performed and costly
Policies and procedures reflect guidance
for PPE use, not mandatory (open to
interpretation by staff nurses)
Unknown cost impact for meeting the
USP <800> Standards for PPE use
No system-defined comprehensive list of
HDs, and no risk assessment for all HDs
No standard work process for PPE
utilization with HD administration
Beliefs and attitudes of nurses that PPE is
a personal choice
No audit tools to measure compliance
with USP <800> Standards for PPE use
Threats

•

•
•

•

Unknown costs associated with PPE
equipment, environmental testing for
residues, and health monitoring of staff
for HD exposure/no known HD limits like
radiation oncology practice
Maintaining and recruiting nurses to work
in high-risk exposure environment
Decrease in funding for infusion services
with 21st Century Cures Act. Political
climate related to healthcare structural
changes within the political parties as to
what changes will be implemented
Deadline extended for implementation of
USP <800> regulations
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Appendix L: Proposed Budget
Type of Expense

Cost

Staff Training on “Observation of PPE Use Tool”
(NP, CNL, Clinical Nurse Educator, Pharmacist)
– 1 hour discussion

$75/hr. x 7 persons = $525

Staff Training on “Hazardous Drug
Administration Safe-Handling Checklist Tool” (1
Clinical Nurse Educator, 2 Relief Charge Nurses,
2 Nurse Practitioners, 2 Pharmacists)

$75/hr. x 7 persons = $525

Expert Panel Discussion for Staff

Complimentary Time from Cancer Committee
Budget
($1,200 in kind)

Staff training estimate based on $75 (15 nurses) 2hour training

$2,250

USP <800> Compliance: Hazardous Drug Toolkit
for Infusion Nursing (printing)

$1,000

DNP Project Manager = 30 hrs.

$75/hr. x 30 hrs. = $2,250

PPE Supplies including White Preparation trays in
Medication Rooms

$15 per PPE Kit x 15 changes/per nurse/per shift
= $210

Average 5 RNs per day x 10 hrs. = 50 hrs.

x 5 nurses/per day = $1,050 per day x 7
days/week = $7,350 per week

Average nurse # PPE changes per patient (5) x 15
PPE changes per day
Hazardous Waste Bins for PPE and Medical
Waste Disposal per cubicle (35)

$35 per waste bin x 35 cubicles = $1,225 per
week

Additional Workers Compensation Funds for
medical monitoring, HD exposure treatment, and
long-term medical management

Currently under review/organization is selfinsured and committed to employee safety
measures to manage risk.

Estimated Total

$16,385 + ($1200 in kind)
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Appendix M: IRB Approval
To ensure Internal Review Board (IRB) approval is not required for implementation of
the QI project, I will submit the DNP Statement of Non-Research Determination form to my
DNP Committee (see Appendix D), as well as submit a request for project review to the
healthcare systems’ IRB committee.
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Appendix N: Letter of Support from Organization
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Appendix O: Proposed CQI Method and Data Collection Tools
Variable
Name
Nursing Skills

Adherence to
PPE use with
HD
administration
Nurses’ SelfAssessment of
Adherence to
PPE use

Brief
Description
Pre-Intervention
Assessment for
Adherence by
trained observers
in the Cancer
Center
Observation
Adherence

Data
Source
Tool

Tools/Analyzing
Data
PPE Observation
Tool (Hennessey
& Dynan, 2014)

Measurement
Type
Medians and
quartiles of
counts and
percentages

Time
Frame
Four weeks

Tool

Median and
quartiles of
counts and
percentages

Two weeks

Nurses evaluate
their own
perception of
adherence and
compliance to
PPE use with
HD-handling at
their current state

Survey

Observations of
Chemotherapy
Safe-Handling
Adherence
(Colvin, Karius &
Albert, 2016)
Safe Handling
between
Observation and
Self-Assessment
(Colvin, Karius, &
Albert, 2016)

Qualtrics
Survey
Nine-item
questionnaire
that uses a
five-point
Liker-type
response set
ranging from
0 (never) to 4
(always), plus
a “not
applicable”
option.

Two weeks
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Appendix P: Dummy Tables

Table 1: PPE Observation Tool
Location:
Month/ Year: ______________
Observer: ________________
Observation: Compliant with USP
<800> Hospital Policy
Observation type (check box)
Pre-Administration
• Handling bags or syringes
outside the leak-proof
transport bag requires gloves
and gowns
• Handling the closed, zipped
leak-proof bag does not
require gown (gloves are
optional).
Administration
• Hanging bags, attaching
tubing, administering IVP,
IM, and SC requires gloves
and gown.
Discard
• Take down of bags and tubing
that contain or contained
chemotherapy and discarding
syringes after IVP, IM, and
SC requires gown gloves and
gown.
Description of Non-Compliance
Wore no gloves
Wore non-chemotherapy gloves
Wore no gown
Reused gown

#1
Yes
No

#2
Yes
No

#3
Yes
No

#4
Yes
No

#5
Yes
No

#6
Yes
No

#7
Yes
No

#8
Yes
No

#9
Yes
No

#10
Yes
No
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PPE gown worn in non-patient care
area
Chemotherapy at desk or in the nonpatient care area
Additional Comments:
Observation #
Comment

IM – Intramuscular; IVP – Intravenous Push; PPE – personal protective equipment; SC – subcutaneous
Note: For each observation, please indicate “yes” for compliant with safe-handling policy or “no” if not compliant. If “no”, check the corresponding box
for a description of the failure to comply. More than one description may apply to one observation. (Hennessey & Dynan, 2014)
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Table 2: Observations of Chemotherapy Safe-Handling Adherence in Number of Events
Behavior
Handling
Uses absorbent pad on work surface for chemotherapy
agents
Wears one pair of chemotherapy-approved gloves to
remove chemotherapy agents from transport bag
Wears two pairs of chemotherapy-approved gloves to
remove chemotherapy agents from transport bag
Removes outer gloves prior to programming pump
Washes hands
Wears second pair of chemotherapy-approved gloves over
ribbed cuff of gown
Removes gown prior to leaving room
Wears chemotherapy-approved gown, with first pair of
approved gloves under ribbed cuff of gown
Disposes of gloves in a chemotherapy-approved container
after initiating chemotherapy
Disconnecting and discarding
Removes gown prior to leaving room
Wears two pairs of chemotherapy-approved gloves and
chemotherapy-approved gown when handling
chemotherapy
Wraps gauze pad around connection site (CSTD) when
disconnecting chemotherapy tubing, leaving chemotherapy
bag attached
Disposes of gloves in a chemotherapy-approved container
Washes hands
Discards the chemotherapy bag and attached secondary
tubing in chemotherapy-approved waste container
(Colvin, Karius, & Albert, 2016)

Adherence (n)

Observation (n)
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Table 3: Safe-Handling Adherence between Observation and Self-Assessment
Behavior
Double gloved during administration
Removed outer gloves prior to
programming pump
Washed hands after glove removal
post-administration
Double gloved during disconnect
Wrapped gauze pad around connection
site
Removed gown prior to leaving room
at disconnect

Observation Adherence
N
N
%

Self-Assessment Adherence
N
%
p
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Table 4: Safe Handling: PPE Compliance/Visibility Board
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Table 5: Hazardous Drug Administration Safe Handling Checklist (Peer-to-Peer Feedback
Tool)
Nurse’s
Name: _____________________________Date of Review: _________ Pt MR #: ________________
PRIOR TO ADMINISTRATION
1. Gather equipment required for drug administration.
2. Select appropriate gloves for hazardous drug administration.
3. Select appropriate gown for hazardous drug administration.
4. Identify situations when mask and face protection are required.
5. Locate hazardous drug spill kit.
6. Obtain hazardous waste container.
ADMINISTRATION
1. Wash hands and don personal protective equipment before opening drug
delivery bag.
2. Visually inspect the contents of the delivery bag for leaks.
3. Gather IV administration supplies including closed-system drug-transfer
devices.
4. For IV infusions
• Ensure tubing is primed with a nondrug solution.
• Utilize plastic backed absorbent pad under work areas. Remove cap from IV
tubing and connect to patient’s IV device.
• Utilize closed-system drug-transfer device when compatible.
• Tighten locking connections.
• When complete, don personal protective and discontinue IV bag with tubing
intact (do not unspike bag).
• Utilize gauze pads when disconnecting from patient’s IV device when a
closed-system drug-transfer device cannot be used.
5. For IV push medications
• Utilize closed-system drug-transfer device when possible.
• Tighten locking connection.
• When complete, do not recap needle.
• Discard syringe-needle unit in puncture-proof container.
6.
•
•
•
•
•
7.
•
•
•
•
8.
•
•
•

For intramuscular/subcutaneous injections
Utilize closed-system transfer-device when possible.
Attach needle to syringe.
Tighten locking connection.
When complete, do not recap needle.
Discard syringe-needle unit in puncture-proof container.
For oral drugs (tablets/capsules)
If using bar code technology, scan medication prior to removing medication
from packaging.
Don gloves.
Open unit-dose package and place into medicine cup (avoid touching drug or
inside of package).
Avoid touching tablets/capsules.
For oral drugs in liquid form
Obtain drug in final form in appropriate oral syringe.
Don double gloves, gown, and mask with face protection
Use plastic-backed absorbent pad during administration.

YES

NO

INITIALS
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• Discard syringe in hazardous waste container after administration.
POST-ADMINISTRATION
1. Don personal protective equipment.
2. Seal hazardous drug-contaminated supplies in sealable plastic bag for
transport to hazardous waste container.
3. Place sealed plastic bag in hazardous waste container.
4. Remove outer gloves.
5. Close lid on waste container.
6. Decontaminate equipment in the area appropriately.
7. Remove and discard inner gloves.
8. Wash hands thoroughly with soap and water.

Reviewer Signature: _____________________________ Initials: ____________

Comments:

(Polovich & Olsen, 2017)
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Appendix Q: Key Elements of the Toolkit
(LAMINATED FLIPCHART FORMAT)

BASED ON AVAILABLE
EVIDENCE

ALIGNED WITH
POLICY AND
PROCEDURE
MANUAL

PART A
PORTFOLIO OF
EVIDENCE

PRACTICAL FOCUS
FOR FRONT LINE
CLINICANS

PART B
HOW TO IMPLEMENT
INTERVENTIONS

PART C
RESOURCE TOOLS
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